• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Early research shows shark antibodies carrying drugs across blood-brain barrier

January 30, 2017 By Sarah Faulkner

Early research shows shark antibodies carrying drugs across blood-brain barrier
Photo credit: Albert Kok

Danish pharmaceutical company Lundbeck made an undisclosed milestone payment to biotech Ossianix Inc., after experiments showed that shark antibodies effectively shuttled potential drugs across the blood-brain barrier in mice.

The 2 companies established a research collaboration in 2014, focusing on technology development and the delivery of antibody-based therapies across the blood-brain barrier.

Ossianix said that it fuses a therapeutic protein to a shark variable new antigen receptor (VNAR) antibody, which then binds to the blood-brain barrier’s transferrin receptor. The therapeutic protein is carried across the barrier and can eventually bind to its drug target.

Drug developers have long struggled to get large-molecule medicines across the protective barrier. The approach is especially exciting for Lundbeck, which hopes to get drugs into the brain to fight neurological diseases such as Alzheimer’s.

Sharks are the most evolutionarily ancient animal species with an immune system similar to humans.

“Ossianix is delighted that Lundbeck, a global leader in neuroscience drug discovery and development, has recognized the potential of our blood-brain barrier delivery technology and taken a license for the development of a number of CNS products,” Ossianix CEO Frank Walsh said in prepared remarks. “Our technology platform is highly versatile and can deliver high levels of therapeutically relevant antibodies to the brain, providing a new approach to the treatment of neurologic disease.”

“Ossianix has generated a world leading platform for delivering antibodies and potentially other drug agents into the brain with significant potential to benefit patients with diseases in the central nervous system,” Lundbeck’s senior VP of global research Kim Andersen added.

Although the technology is still years away from hitting the market, Andersen pointed out it’s a step forward towards successfully delivering antibody-based medicines into the brain.

Materials from Reuters were used in this report.

Filed Under: Featured, Neurological, Research & Development Tagged With: Lundbeck, Ossianix Inc

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS